Castle Biosciences Stock News

Related Stocks: PING , RLJ , DEA , CSGS , ABBV , HRTX , AVGOP.PFD , WFCPL.PFD , CSTL , DHRPA.PFD , BACPL.PFD , VERX , COR , VNT , LRCX , APLS , SEDG , Z ,

Castle Biosciences (CSTL) said a study showed DecisionDx-SCC provides significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous

Castle Biosciences (CSTL) said a study showed that the combined application of DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq allows for highly accurate analysis of RNA and DNA

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the 24th Annual Needham Growth Conference, Jan. 10, 2022, at 12:30 p.m. Eastern ti

EMC Capital Management grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,847 shares of the company’s stock after purchasing an additional 2,154 shares during the period. Castle Biosciences makes up approximately 0.9% […]

Wall Street brokerages expect that Castle Biosciences, Inc. (NASDAQ:CSTL) will announce $23.43 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Castle Biosciences earnings, with the highest sales estimate coming in at $23.45 million and the lowest estimate coming in at $23.40 million. Castle Biosciences posted sales of [] The post Zacks: Brokerages Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Announce Quarterly Sales of $23.43 Million appeared first on ETF Daily News .

Castle Biosciences, Inc. (NASDAQ:CSTL) dropped 6.2% during mid-day trading on Thursday . The company traded as low as $42.94 and last traded at $42.94. Approximately 5,706 shares changed hands during trading, a decline of 98% from the average daily volume of 243,368 shares. The stock had previously closed at $45.76. CSTL has been the topic []

Castle Biosciences announced it has completed its acquisition of Cernostics, Inc.

Castle Biosciences Inc. (NASDAQ:CSTL) concluded the trading at $41.43 on Friday, December 03 with a fall of -1.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $41.92 with its price kept floating in the range of $40.225 and $42.58 on the Castle Biosciences Inc. (CSTL) Is A Stock Worth Accumulating At Current Levels Read More »

Castle Biosciences, Inc. (NASDAQ:CSTL) reached a new 52-week low during trading on Monday . The company traded as low as $41.14 and last traded at $41.48, with a volume of 8168 shares trading hands. The stock had previously closed at $43.12. A number of research analysts have commented on the stock. SVB Leerink reduced their []

Prudential Financial Inc. acquired a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,901 shares of the companys stock, valued at approximately $286,000. A number of other large investors have also recently bought and []

Castle Biosciences Inc (CSTL) shares closed 2.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 35.8% year-to-date, down 3.0% over the past 12 months, and up 101.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 53.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 185.9% The company's stock price performance over the past 12 months beats the peer average by -35.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Brokerages expect Castle Biosciences, Inc. (NASDAQ:CSTL) to report sales of $23.43 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Castle Biosciences earnings. The highest sales estimate is $23.45 million and the lowest is $23.40 million. Castle Biosciences reported sales of $17.30 million in the same quarter last year, which [] The post Zacks: Analysts Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Announce Quarterly Sales of $23.43 Million appeared first on ETF Daily News .

Castle Biosciences Inc (CSTL) shares closed today at 0.8% above its 52 week low of $42.78, giving the company a market cap of $1B. The stock is currently down 33.2% year-to-date, up 2.9% over the past 12 months, and up 109.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 43.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 203.2% The company's stock price performance over the past 12 months beats the peer average by -237.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.